RxDoctor Payments Data

Arian Baker, MD

Family Medicine · Tallahassee, FLNPI 1255999371

Payments from drug & device makers

$6,198in general payments, 2019–2025

Across 372 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$928
  • AbbVie$580
  • Lilly USA, LLC$580
  • Boehringer Ingelheim$577
  • Amgen$518
  • Abbott$464
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$6,198100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,198 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$31,596
Medicare patients
72
Services billed
1,096

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide59$64,895
OzempicSemaglutide42$55,716
EliquisApixaban54$42,115
XareltoRivaroxaban13$16,433
FarxigaDapagliflozin Propanediol12$12,569
MyrbetriqMirabegron17$7,427
Sucralfate13$2,056
Atorvastatin Calcium118$1,336
Gabapentin50$1,201
Pantoprazole Sodium67$1,191
Omeprazole60$1,178
Losartan Potassium135$1,169
Duloxetine Hcl35$1,024
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$993
Cyclobenzaprine Hcl50$917

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$580$64,89559 claims
Novo NordiskOzempic$928$55,71642 claims
PfizerEliquis$405$42,11554 claims
AstraZenecaFarxiga$373$12,56912 claims
Astellas Pharma US IncMyrbetriq$89$7,42717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →